Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...
10h
Clinical Trials Arena on MSNAnaptysBio achieves ‘highest ever’ results in Phase II rheumatoid arthritis trialAnaptysBio’s Phase IIb trial of its rheumatoid arthritis (RA) treatment, rosinilimab, has seen some patients achieve the ...
19h
Investor's Business Daily on MSNAnaptysBio Whipsaws On Promising Results In Rheumatoid Arthritis TreatmentAnaptysBio stock whipsawed Wednesday despite promising results for its experimental rheumatoid arthritis treatment.
AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...
Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs.
Indian scientists have created an innovative self-actuating drug delivery system for Rheumatoid Arthritis, providing precise ...
Rheumatoid arthritis (RA) is an inflammatory arthritis characterized by chronic joint inflammation, cartilage degradation, and bone erosion.
The positive trial results have not only demonstrated rosnilimab's potential in treating RA but have also validated AnaptysBio's scientific approach in targeting PD-1 co-inhibitory receptors on ...
Intermittent fasting may benefit antioxidant and inflammatory markers in postmenopausal women with rheumatoid arthritis.
Patients with rheumatoid arthritis are associated with an increased risk for heart failure, particularly heart failure with preserved ejection fraction.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results